NCT03917225 - A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

August 13, 2020

Study Completion Date

September 14, 2020

Conditions

Friedreich Ataxia

Interventions

DRUG

MIN-102

Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.

DRUG

Placebo

Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.

Trial Locations (5)

28046

Hospital Universitario La Paz, Madrid

52074

Universitätsklinikum RWTH, Aachen

75646

ICM, Groupe Hospitalier Pitié Salpêtrière, Paris

B-1070

Hôpital Erasme-ULB, Brussels

Unknown

Hospital Sant Joan de Déu, Barcelona